Skip to main content

Table 2 Mean changes from baseline in body weight, BMI, fasting blood glucose, and HbA1c levels

From: Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care

  

Total (n = 200)

Male (n = 113)

Female (n = 87)

M

SD

p-value

M

SD

p-value

M

SD

p-value

Body weight (kg)

Start of treatment

74.76

16.72

< 0.001

80.34

19.01

0.005

67.53

9.08

< 0.001

After 1 year of treatment

71.37

10.59

75.98

9.17

65.39

9.28

BMI (kg/m2)

Start of treatment

27.95

2.96

< 0.001

27.85

2.72

< 0.001

28.09

3.25

< 0.001

After 1 year of treatment

27.02

3.07

26.90

2.81

27.18

3.40

Glucose (mg/dL)

Start of treatment

150.88

29.74

< 0.001

151.56

28.26

< 0.001

150.00

31.71

< 0.001

After 1 year of treatment

136.93

24.10

139.10

24.79

134.11

23.00

HbA1c (%)

Start of treatment

7.33

0.83

0.037

7.29

0.75

0.234

7.38

0.92

0.076

After 1 year of treatment

7.22

0.77

7.21

0.79

7.24

0.75

  1. Abbreviations: HbA1c Glycated hemoglobin, BMI Body mass index, SD Standard deviation